이 에피소드에 관해
In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health.
- ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip.
- A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts.
- GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains.
- Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction.
- Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health.
----------
News & References:
- ‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/
- Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/
- Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/
- Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/
- Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/
- ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/
----------
Host:Phil Newman: https://qrco.de/bgXpNY
영어
미국
전사 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
이 팟캐스트의 다른 에피소드
In this week’s Longevity News Roundup, Phil Newman examines the developments reshaping longevity and healthspan, from a major biotech investment in hair loss to AI-driven drug repurposing, the industry’s communication challenge, biological-age testing at population scale, and the push to manufactur…
Guests:
Paola Telfer
Founder and CEO of Sens.ai
LinkedIn: www.linkedin.com/in/paolatelfer/
Website: sens.ai/
Eric Verdin, MD
President and CEO of the Buck Institute for Research on Aging
LinkedIn: www.linkedin.com/in/eric-verdin-md/
Website: www.buckinstitute.org/
----------
What if we could tr…
What would have to be true for AI to genuinely change the trajectory of human aging?
The answer is more complicated than simply discovering an “anti-aging drug.” AI is already compressing parts of drug discovery, with one AI-designed candidate reaching Phase 2 trials in under 30 months, while new …
Guest: Joanna Bensz
Founder & CEO of Longevity Center and Longevity Academy
LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/
Website: https://longevity-academy.com/, https://longevity-center.eu/
----------
What happens when longevity becomes a global industry before the medical sys…
면책 조항: 이 페이지에 포함된 팟캐스트와 작품은 Longevity.Technology에서 가져온 것입니다. 이 팟캐스트는 소유자의 재산이며 Listen Notes, Inc.와 제휴하거나 보증하지 않습니다.